Combined lung and heart extraction in clinical transplantation.

The anatomical conditions for single lung and double lung transplantation allow a heart transplant and one or two lung transplants to be performed in two or three different recipients from a single donor with healthy lungs. The extraction of the heart and lung block for the purposes of these separate transplantations is described on the basis of our experience of 6 single lung transplants with 6 extractions for cardiac transplantation in different recipients, of a total of 8 lung transplants. We report these 12 successful operations and the particular technical modalities of cardiopulmonary extraction for separate transplantation. After cannulation for cooling of the abdominal viscera (kidneys, liver, pancreas), thoracic and mediastinal dissection, cardioplegia and surface pulmonary cooling by iced saline on the collapsed lungs, the heart and lungs were extracted as a single block and were separated ex situ. After periods of cold ischaemia of 1 h to 3 h 30 min for the hearts and 1 h 30 min to 5 h for the lungs, the immediate and medium term functions were satisfactory. Logistical difficulties involved in matching the population of recipients have prevented the grafting of three different recipients up until now. These successes make it essential to preserve the lungs from donors with healthy lungs. A rigorous coordination between the various transplantation teams helps to avoid competition between the three types of transplantation: heart-lung, double lung and single lung.

Spiramycin concentrations in lung tissue.

Spiramycin concentrations in lung tissue were studied in patients undergoing pulmonary surgical procedures. The first group of six patients received 500 mg spiramycin iv 16 h before surgery and 500 mg at anaesthetic induction (total 1 g). The second group of six patients received three doses of 500 mg spiramycin iv 24, 16 and 8 h before surgery, and 500 mg at anaesthetic induction (total 2 g). Samples were taken from lung tissue, pleura, fat tissue and muscle. In group 1, the mean lung tissue concentration of spiramycin was 1.15 +/- 0.14 mg/kg and 7.99 +/- 2.02 mg/kg in group 2 (P less than 0.02). The differences in concentration in pleura, fat tissue and muscle samples between treatment groups 1 and 2 were not statistically significant.